BCYC insider files Form 144 to sell 102 shares on Nasdaq
Rhea-AI Filing Summary
Bicycle Therapeutics plc (BCYC) filed a Form 144 notice reporting a proposed sale of 102 shares of common stock through Stifel Nicolaus & Company Inc with an aggregate market value of $872, intended for sale on 10/02/2025 on Nasdaq. The filing discloses that 218 shares were acquired on 10/02/2025 as Restricted Stock Units from the issuer and were paid as equity compensation. The form also reports that the filer sold 411 shares on 07/02/2025 for gross proceeds of $3,058. The notice includes the statutory representation that the seller does not possess undisclosed material adverse information about the issuer.
Positive
- Form 144 was filed, disclosing the proposed sale of 102 shares
- Broker named: Stifel Nicolaus & Company Inc
- Acquisition of 218 shares on 10/02/2025 was via Restricted Stock Units and paid as equity compensation
- Previous sale disclosed: 411 shares sold on 07/02/2025 for $3,058
Negative
- None.
Insights
Form 144 filed to report an insider's proposed sale of 102 shares for $872 on 10/02/2025.
The filing identifies the broker as Stifel Nicolaus & Company Inc and specifies the market where the shares will be sold: Nasdaq. It also documents the acquisition of 218 shares on 10/02/2025 as Restricted Stock Units paid via equity compensation.
The form lists a prior disposition of 411 shares on 07/02/2025 producing $3,058 in gross proceeds. This information is procedural disclosure required under Rule 144 and confirms compliance steps for an insider sale; no additional material facts or regulatory actions are disclosed in the filing.